Holen Sie sich die Stockscreener-App
744.90
0.13%
-1.7127
Schlusskurs vom Vortag:
$746.61
Offen:
$754.55
24-Stunden-Volumen:
83,037
Relative Volume:
0.11
Marktkapitalisierung:
$78.79B
Einnahmen:
$14.34B
Nettoeinkommen (Verlust:
$4.50B
KGV:
17.92
EPS:
41.5626
Netto-Cashflow:
$3.77B
1W Leistung:
-1.87%
1M Leistung:
-7.17%
6M Leistung:
+33.15%
1J Leistung:
+9.55%
1-Tages-Spanne:
$744.68
$758.98
1-Wochen-Bereich:
$744.00
$788.69
52-Wochen-Spanne:
$476.49
$821.11
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Firmenname
Regeneron Pharmaceuticals Inc
Sektor
Branche
Telefon
(914) 847-7000
Adresse
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
745.24 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
471.00 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
ARGX
Argen X Se Adr
|
701.00 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.99 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.45 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-06 | Eingeleitet | Barclays | Overweight |
| 2026-01-07 | Hochstufung | BofA Securities | Underperform → Buy |
| 2025-12-03 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-24 | Eingeleitet | HSBC Securities | Buy |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Perform |
| 2025-08-14 | Eingeleitet | Rothschild & Co Redburn | Buy |
| 2025-06-30 | Herabstufung | Argus | Buy → Hold |
| 2025-05-30 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-02-05 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Herabstufung | UBS | Buy → Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-09-24 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Eingeleitet | Bernstein | Outperform |
| 2024-01-12 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Bestätigt | Oppenheimer | Perform |
| 2023-06-28 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Hochstufung | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Hochstufung | Jefferies | Hold → Buy |
| 2023-03-23 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Hochstufung | Cowen | Market Perform → Outperform |
| 2023-01-20 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Hochstufung | Jefferies | Underperform → Hold |
| 2022-09-09 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Eingeleitet | Jefferies | Underperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2022-01-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-12-07 | Fortgesetzt | Cowen | Market Perform |
| 2021-12-06 | Eingeleitet | Goldman | Buy |
| 2021-11-19 | Fortgesetzt | BMO Capital Markets | Outperform |
| 2021-11-05 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-01-25 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-10-05 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Hochstufung | SunTrust | Hold → Buy |
| 2020-05-26 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-04-17 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Eingeleitet | The Benchmark Company | Hold |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-02-26 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Hochstufung | Jefferies | Hold → Buy |
| 2020-02-11 | Hochstufung | Argus | Hold → Buy |
| 2019-12-24 | Eingeleitet | Raymond James | Mkt Perform |
| 2019-12-16 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Eingeleitet | SunTrust | Hold |
| 2019-11-07 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
Alle ansehen
Regeneron Pharmaceuticals Inc Aktie (REGN) Neueste Nachrichten
Regeneron Pharmaceuticals Inc Stock (ISIN: US7739031091) Faces Pressure Amid R&D Surge and Margin Sq - AD HOC NEWS
Quadrature Capital Ltd Has $34.31 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Mackenzie Financial Corp Raises Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Quadrant Capital Group LLC Purchases 1,564 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Capital Research Global Investors Raises Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
In 2036, Investors Will Regret Not Loading Up on This Multibagger in the Making - The Globe and Mail
A Look At Regeneron Pharmaceuticals (REGN) Valuation After Positive Obesity Phase 3 Trial Results - Yahoo Finance
Regeneron Science Talent Search: Jericho High senior Ashka Shah recounts experience at finals in D.C. - Newsday
Regeneron: Fairly Valued Now After A Stellar Upswing (NASDAQ:REGN) - Seeking Alpha
WINTON GROUP Ltd Grows Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Franklin Resources Inc. Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Richard Bernstein Advisors LLC Sells 2,449 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Legal & General Group Plc Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Capital World Investors Acquires 32,348 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Stock Position Lowered by Capital International Inc. CA - MarketBeat
Capital International Investors Trims Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Capital Group Private Client Services Inc. - MarketBeat
Regeneron Science Talent Search 2026 Recognizes America’s Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Science, and Blood Cancer Treatment - The Manila Times
Regeneron Science Talent Search 2026 Recognizes America’s - GlobeNewswire
Will Positive Obesity Data and Dupixent Expansion Efforts Change Regeneron Pharmaceuticals' (REGN) Narrative? - simplywall.st
Regeneron Science Talent Search 2026 Recognizes America’s Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Science, and Blood Cancer Treatment - GlobeNewswire Inc.
Jefferies raises Regeneron stock price target on obesity drug data - Investing.com
Price Over Earnings Overview: Regeneron Pharmaceuticals - Benzinga
REGN: Dupixent and EYLEA HD fuel growth as pivotal pipeline readouts approach in 2024–2025 - TradingView
Capital International Ltd. CA Sells 5,999 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Capital International Sarl Has $26.31 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Swiss National Bank Has $172.06 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Russell Investments Group Ltd. Has $128.61 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Korea Investment CORP Purchases 5,181 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Cowen Maintains Buy on Regeneron Pharmaceuticals, Inc. (REGN) March 2026 - Meyka
Regeneron's GLP-1/GIP obesity drug succeeds in late-stage trial - TechTarget
Regeneron (REGN) Reports Positive Phase 3 Results for Obesity Dr - GuruFocus
Pfizer Tries Again In Atopic Dermatitis, This Time With A Trispecific - Citeline News & Insights
Regeneron stock maintained at Buy by Truist on obesity drug data - Investing.com Canada
Regeneron’s Weight Loss Partner Hansoh Delivers Much-Needed Phase 3 Win in China - BioSpace
Sienna Gestion Sells 9,627 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron-licensed obesity drug shows positive phase 3 results in China (REGN:NASDAQ) - Seeking Alpha
Vinva Investment Management Ltd Increases Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron (REGN) Advances in Obesity Treatment with Promising Tr - GuruFocus
Olatorepatide obesity treatment licensed by Regeneron demonstrates positive phase 3 results in Chinese patients - marketscreener.com
Olatorepatide Obesity Treatment Licensed by Regeneron Demonstrates Positive Phase 3 Results in Chinese Patients - The Manila Times
Olatorepatide Obesity Treatment Licensed by Regeneron Demonstrates Positive Phase 3 Results in ... - bdtonline.com
Jefferies Financial Group Inc. Acquires Shares of 25,535 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Natixis Advisors LLC Acquires 7,084 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by First Trust Advisors LP - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Victory Capital Management Inc. - MarketBeat
Pinnacle Associates Ltd. Has $47.34 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Prevail Innovative Wealth Advisors LLC Acquires Shares of 7,628 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Rhenman & Partners Asset Management AB - MarketBeat
Grantham Mayo Van Otterloo & Co. LLC Trims Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Lowered to "Hold" Rating by Wall Street Zen - MarketBeat
Finanzdaten der Regeneron Pharmaceuticals Inc-Aktie (REGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):